NEW YORK, Sept. 8, 2007 LAWFUEL – The Class Action Newswire — The Rosen Law Firm announced today that investors have until October 12, 2007 to request to serve as a lead plaintiff in the securities class action lawsuit against Northwest Biotherapeutics, Inc. (“Northwest”) (OTCBB: NWBO).
The class action is on behalf of purchasers of Northwest stock from July 9, 2007 through July 16, 2007, inclusive.
To join the Northwest Biotherapeutics securities litigation as a plaintiff or for further information, please call Laurence Rosen, Esq.
or Phillip Kim, Esq. toll-free at 866-767-3653 or email lrosen@rosenlegal.com or pkim@rosenlegal.com.
UNTIL A CLASS IS CERTIFIED, YOU ARE NOT PERSONALLY REPRESENTED BY COUNSEL UNLESS YOU RETAIN AN ATTORNEY.
The Complaint asserts that on July 9, 2007 the Company issued a press release that misleadingly suggested that the Company had received authorization to begin commercial sale of its DCVax-Brain cancer medication in Switzerland, causing an immediate rise in the price of Northwest’s stock. On July 16, 2007, the Company admitted that it had not received any authorization for the sale and use of its product.
This corrective disclosure caused the price of Northwest stock to plummet, damaging investors.
The Rosen Law Firm has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud. The Rosen Law Firm represents investors throughout the nation, concentrating its practice in securities class actions.
